Your browser doesn't support javascript.
loading
Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia.
Liu, Yabo; Li, Huibo; Zhao, Yanqiu; Li, Dandan; Zhang, Qian; Fu, Jinyue; Fan, Shengjin.
Afiliação
  • Liu Y; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Li H; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Zhao Y; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Li D; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Zhang Q; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Fu J; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Fan S; Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Bioengineered ; 13(2): 2296-2307, 2022 02.
Article em En | MEDLINE | ID: mdl-35034552
ABSTRACT
Long non-coding RNAs (LncRNAs) exert important regulatory roles in chronic myeloid leukemia (CML). In this study, we aimed to investigate the potential role and molecular mechanism of lncRNA ADORA2A antisense RNA 1 (ADORA2A-AS1) in CML. We found that the expression of ADORA2A-AS1 was upregulated in CML. Further, knockdown of ADORA2A-AS1 inhibited the proliferation, induced apoptosis, arrested cell cycle, and enhanced imatinib sensitivity in CML cells. Besides, ADORA2A-AS1 promoted the expression of transforming growth factor-beta receptor 1 (TGFBR1) and ATP binding cassette subfamily C member 2 (ABCC2) via sponging miR-665, thereby exerting a tumor-promoting activity. Collectively, our results confirmed the oncogenic effect of ADORA2A-AS1 in CML, indicating that ADORA2A-AS1 is a promosing therapeutic target for CML.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Neoplásico / Leucemia Mielogênica Crônica BCR-ABL Positiva / RNA Antissenso / Resistencia a Medicamentos Antineoplásicos / Proliferação de Células / Técnicas de Silenciamento de Genes / Mesilato de Imatinib Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Bioengineered Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Neoplásico / Leucemia Mielogênica Crônica BCR-ABL Positiva / RNA Antissenso / Resistencia a Medicamentos Antineoplásicos / Proliferação de Células / Técnicas de Silenciamento de Genes / Mesilato de Imatinib Tipo de estudo: Diagnostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Bioengineered Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China